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Abstract
Background: The ability of oligodendrocyte progenitor cells (OPCs) to give raise to myelin forming cells during
developmental myelination, normal adult physiology and post-lesion remyelination in white matter depends on
factors which govern their proliferation, migration and differentiation. Tissue plasminogen activator (tPA) is a serine
protease expressed in the central nervous system (CNS), where it regulates cell fate. In particular, tPA has been
reported to protect oligodendrocytes from apoptosis and to facilitate the migration of neurons. Here, we investigated
whether tPA can also participate in the migration of OPCs during CNS development and during remyelination after
focal white matter lesion.
Methods: OPC migration was estimated by immunohistological analysis in spinal cord and corpus callosum during
development in mice embryos (E13 to P0) and after white matter lesion induced by the stereotactic injection of
lysolecithin in adult mice (1 to 21 days post injection). Migration was compared in these conditions between wild
type and tPA knock-out animals. The action of tPA was further investigated in an in vitro chemokinesis assay.
Results: OPC migration along vessels is delayed in tPA knock-out mice during development and during remyelination.
tPA enhances OPC migration via an effect dependent on the activation of epidermal growth factor receptor.
Conclusion: Endogenous tPA facilitates the migration of OPCs during development and during remyelination after
white matter lesion by the virtue of its epidermal growth factor-like domain.
Keywords: Multiple sclerosis, Myelin, Epidermal growth factor, Endothelial cells, Vasophilic migration, Lysolecithin,
Spinal cord, Development
Background
Spontaneous remyelination enables regeneration of white
matter after lesions. This process is possible thanks to the
presence, in the adult central nervous system (CNS),
of oligodendrocyte precursor cells (OPCs) which have
the capacity to replace dead oligodendrocytes and to
form new myelin sheaths at the sites of demyelination
[1]. Spontaneous remyelination is linked to the ability
of OPCs to proliferate, migrate and differentiate into
mature oligodendrocytes in physiological conditions
(during development and in adulthood) and in response
to injuries.
This process is important in various pathological
situations in the CNS, including multiple sclerosis
(MS). In relapsing-remitting MS (RR-MS), the most
frequent form of the disease, patients experience suc-
cessive phases of relapses (worsening of symptoms)
and remissions (neurological improvement), which are
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considered to mostly follow a pattern of successive
demyelination and remyelination, giving rise to the
so-called ‘shadow plaques’. However, the extent of
remyelination is very variable among patients, and, in
most cases, incomplete [2, 3]. A second form of MS
exists, called primary progressive MS (PP-MS), in
which the disease progresses gradually without remis-
sion phases. Finally, in a significant subset of RR-MS
patients, the course of the disease eventually shifts to
a progressive course, termed secondary progressive
MS (SP-MS). In these progressive forms of MS (PP-
MS and SP-MS), although partial remyelination has
been observed [4], its efficiency is not sufficient for
counterbalance the progression of disease. Therefore,
there is great interest in understanding the endogen-
ous factors which govern spontaneous remyelination
in order to explain why this process fails in the differ-
ent forms of MS. This better knowledge could help
designing new therapeutic strategies aiming at boost-
ing the capacity of remyelination in MS and other de-
myelinating diseases [5, 6].
Most remyelinating oligodendrocytes are derived from
adult OPCs, which have a widespread distribution
throughout the CNS [7]. Effective remyelination depends
in great part on the ability of these OPCs to reach the
demyelinated areas. Migration of OPCs depends on the
action of chemotactic factors able to attract or repulse
OPCs, thus controlling the direction of migration, and
chemokinetic factors able to accelerate or slowdown
OPCs, thus controlling the speed of migration [8]. Al-
though embryonic OPCs, responsible for myelination
during development, and adult OPCs, responsible for
remyelination after lesion, form two distinct populations,
developmental myelination and post-lesion remyelina-
tion share mechanistic aspects [9, 10]. For this reason,
lessons learned from the description of myelination
during development can be useful to better understand
the chemotactic and chemokinetic factors involved in
remyelination.
Tissue-type plasminogen activator (tPA) is a serine
protease long described for its role in fibrinolysis in the
circulation. Beyond this property, tPA has been re-
ported to be expressed by many cell types in the brain,
including oligodendrocytes [11, 12] and to exert mul-
tiple functions in the healthy and diseased CNS [13].
Among these functions, tPA has been shown to facili-
tate neuron migration during development [14]. tPA
has also been shown to influence neuron and OPC
survival, in particular by exerting anti-apoptotic effects
on these cells via the action of a structural domain
homologous to epidermal growth factor (EGF) [11, 15],
a growth factor previously described to increase OPC
migration [16]. However, whether tPA could influence
OPC migration was never investigated so far.
In the present study, we hypothesized that tPA could
facilitate OPC migration based on the following facts
described above: (i) tPA facilitates neuronal migration
[14], (ii) tPA can act on OPCs through its EGF-like
domain [11] and (iii) EGF increases OPC migration
[16]. To study this, we first explored the migration of
OPCs in the developing spinal cord and telencephalon
(giving raise to corpus callosum, the vastest white
matter area in murine brain) by comparing wild type
(WT) and tPA knock-out (tPA−/−) animals. Because we
observed a delay in OPC migration during myelination,
we studied whether a similar phenotype could appear
in adult tPA−/− mice after focal white matter lesion. In-
deed, remyelination was also delayed in these animals,
indicating that endogenous tPA could facilitate OPC
migration. Finally, we show here that tPA exerts a che-
mokinetic effect on OPCs in vitro, through its domain
of homology with EGF.
Methods
Ethical statement
Experiments were performed in our laboratory (agree-
ment number D14118001) in accordance with French
ethical laws (act no. 87–848; Ministère de l’Agriculture
et de la Forêt), European Union Council Directives of
November 24, 1986 (2010/63/EEC) and guidelines for
the care and use of laboratory animals. Experiments
have been approved by the ethics committee n°52 on
animal experiments (CENOMEXA) and by the French
Ministry of Research under the project license number
02653.2 (30/06/2016). None of the experimental procedures
induced animal mortality. All experiments were performed
following the ARRIVE guidelines (www.nc3rs.org.uk),
including randomization of treatment as well as analysis
blind to the treatment.
Animals and surgery
Wild type and tPA−/− [17] C57BL6-J mice (aged 2 months,
CURB, Caen, France) were housed in a temperature-
controlled room on a 12 h light/12 h dark cycle with
access to food and water ad libitum. Demyelination was
induced by stereotaxic injection of 1% LPC (L1381, Sigma-
Aldrich) in 0.1 M phosphate-buffered saline (Sigma-
Aldrich). Mice were deeply anaesthetized with isoflurane
(induction 5%, maintenance 2.5% in 70/30% NO2/O2).
Rectal temperature was maintained at 37 °C using a
feedback-regulated heating pad. Mice were placed in a
stereotaxic frame. The demyelinating agent was injected
unilaterally into the corpus callosum with a microinjec-
tion pipette (Hecht Assistent), using the following
stereotaxic coordinates: 1.1 mm anterior to the bregma,
2.7 mm lateral to the bregma and 1.3 mm deep from the
cortex surface, using an angle of 30°. Scalp incisions
were closed with Vetbond thread.
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Magnetic resonance imaging (MRI) analysis
MRI analyses were performed on 1, 3, 7, 14 and 21 days
post-injection. Experiments were carried out on a Phar-
mascan 7 T MRI (Bruker, Germany). T2-weighted images
were acquired using a multislice/multiecho sequence: TE/
TR 12.7 ms/2500 ms and a flip angle of 180° with spatial
resolution of 70 μm*70 μm and slice thickness 350 μm in-
terpolated to an isotropic resolution of 70 μm (acquisition
time = 8 min). Lesion sizes were quantified on these im-
ages by an experimenter blinded to the genotype using
ImageJ (NIH software v1.49e, National Institute of Health,
Bethesda, MD, USA).
Immunohistochemistry
1, 3, 7, 14 and 21 days post-injection mice were deeply
anesthetized and perfused transcardially with 20 ml of
cold heparinized NaCl 0.9%, followed by 2% paraformal-
dehyde and 0.2% picric acid in 150 ml of 0.1 M sodium
phosphate buffer, pH 7.4. Brains were removed, washed
in veronal buffer containing 20% sucrose, and frozen in
Tissue-Tek (Miles Scientific). Embryos were collected at
noon of embryonic days. Heads and trunks were fixed in
2% paraformaldehyde and 0.2% picric acid for 24 h,
cryoprotected in veronal buffer containing 20% sucrose,
and frozen in Tissue-Tek. Cryomicrotome-cut sections
(10 μm) were collected on poly-lysine slides and stored at
−80 °C before processing. Sections were incubated over-
night at room temperature with a primary antibody or a
cocktail of primary antibodies (Additional file 1: Table S1)
diluted in veronal buffer containing 0.25% Triton ×100.
Three rinses were performed in veronal buffer at room
temperature. All secondary antibodies (Additional file 1:
Table S1) were diluted (1:600) in veronal buffer containing
0.25% Triton × 100. Incubation was performed at room
temperature for 1h30min followed by three washes.
Washed sections were coverslipped with antifade medium
containing DAPI. For each set of immunostaining, the fol-
lowing controls were systematically performed on adjacent
sections: Omission of primary or secondary antibodies in
single immunolabelling experiments resulted in no spe-
cific labelling. Additionally, the absence of cross-reactivity
between the antibodies in multi-immunolabelling experi-
ments was demonstrated by omission of one of the pri-
mary antibodies and consecutively the absence of relevant
signal detection with the cocktail of secondary antibodies.
Images were digitally captured using a Leica DM6000B
microscope-coupled coolsnap camera (ORCA Flash 4-
LT; Hamamatsu), visualized with Metamorph 5.0 soft-
ware (Molecular Devices) and further processed using
ImageJ1.5 h software (NIH).
3D reconstruction
Images were collected using a Leica SP5 confocal
microscope with a 100× oil-immersive objective (Leica
Microsystems). Confocal images were taken at a 1024 ×
1024 pixel resolution with a z-step of 0.45 μm. The 3D
structure was reconstructed from confocal images using
Imaris software (version 5.5, Bitplane, Zurich, Switzerland).
Volume and surface functions were used.
Cell counting and quantification of MBP
immunofluoresence
The total number of positive cells was counted in the
lesion area. In the contralateral corpus callosum, an
equivalent area for each mice was selected and the
number of positive cells was counted in the selected
area. During development, the area of the whole spinal
cord or telencephalon section was measured and the
total number of positive cells was counted in the sec-
tion. For MBP immunofluorescence quantification, the
mean gray value was evaluated in the lesion area or the
equivalent contralateral area. All quantitative analyses
were done in three randomly selected sections per
mouse and the individual values for the number of
cells/mm2 or for fluorescence intensity for each mouse
was estimated by averaging the values of all counted
sections for the same mouse.
Oligodendrocyte precursor cell (OPC) cultures
Primary mixed glial cultures were prepared according
to the modified technique of McCarthy and de Vellis
[18]. Briefly, forebrains of P0-P1 newborn Wistar rats
were dissociated mechanically and resuspended in
DMEM (D5671, Sigma-Aldrich) containing 10% fetal
bovine serum, 10% horse serum, 2 mM glutamine
(25030024, Thermo Fisher Scientific), 0.5% penicillin
streptomycin (15140122, Thermo Fisher Scientific) and
plated on poly-D-lysine-coated (0.1 mg/mL) (P6407,
Sigma-Aldrich) 75 cm2 flasks (Nunc, Wiesbaden,
Germany). After 10 days in culture the flasks were
shaken at 210 rpm at 37 °C for 3 h to remove loosely
adherent microglia. The remaining OPCs present on
the top of the confluent monolayer of astrocytes were
dislodged by shaking overnight at 270 rpm. The cell
suspension was filtered through a 40 μm nylon mesh
and then pre-plated on bacterial grade Petri dishes for
1 h. The nonadherent OPCs that remained in suspen-
sion were recovered, filtered through a 40 μm nylon
mesh, and plated again on bacterial grade Petri dishes
for 30 min. The resulting enriched OPCs cell suspen-
sion was counted and seeded in accordance to the
assay performed.
Cell proliferation assay
OPC proliferation was estimated by examination of the
cultures under bright-field microscopy and quantified
with WST-1 assay. Briefly, oligodendrocyte precursor
cell were plated on poly-D-lysine-coated (0.1 mg/mL),
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24-well (2 cm2/well) tissue culture dish at a density of
6 × 104 cells/cm2 and cultured in DMEM (D5671,
Sigma-Aldrich) supplemented with recombinant
PDGF-AA (PHG0035, Thermo Fisher Scientific, 5 ng/
ml) and bFGF (15140–122, Invitrogen, 5 ng/ml), N2
supplement (17502–048, Thermo Fisher Scientific),
2 mM glutamine (25030024, Thermo Fisher Scien-
tific), 0.5% penicillin streptomycin (15140122, Thermo
Fisher Scientific). Cells were used for proliferation
assay at 2 days in vitro. To assess cell proliferation,
WST-1 reagent (Roche Applied Science, Indianapolis,
IN), a tetrazolium salt, was added to the medium and
incubated for 1 h at 37 °C in 5% CO2. After WST-1
incubation with cells, bathing media from 24-well
plates was transferred into 96-plates and cell prolifer-
ation was determined by measuring the absorbance at
460 nm (reference wavelength 600 nm) for cleavage of
the tetrazolium salt to formazan. A portion of the
wells were used to evaluate the number of cells at the
beginning of the experiment (t0 value), by adding
WST-1 directly to the medium of 3 wells. Other wells
were treated with tPA, vehicle or control medium by
renewing medium. After 24 h of treatment, cells were
incubated with WST-1 to estimate the number of cells
after treatment (t1 value). Percentage of proliferation
during 24 h (with or without treatment) was calculated
using the following formula: [% of proliferation = ((t1
value/t0 value) × 100)-100].
Chemokinesis assay and immunocytochemistry
OPC migration was assessed in chemotaxis chambers
with polycarbonate membranes (pore size 8 μm; Corning
Costar). The membranes were coated with poly-L-ly-
sine (0.1 mg/mL) and laminin (0.1 mg/mL) (23017015,
Thermo Fisher Scientific) as described previously [19].
OPCs from rat were seeded (40000 cells/transwell) in
the upper chamber while in the lower compartment
the DMEM culture medium containing N2 supple-
ment, 2 mM glutamine, penicillin streptomycin was
supplemented for the different experimental groups as
follows: Control; FGF2 (0.2 μg/mL; RD Systems 233-
FB); tPA 0.1, 1, 10 μg/mL (Actilyse; BoehringerIngel-
heim); tPA buffer (vehicle); tPA 10 μg/mL + inhibitor
of EGFR kinase, AG1478 (5 μM; 1276, Tocris);
AG1478 (5 μM); tPA GGACK 10 μg/mL. Concerning
experimental groups, tPA 10 μg/mL + AG1478 5 μM
and AG1478 5 μM, the cells were also treated one
hour before and during the experiment with the EGFR
blocker AG1478 5 μM and the rest of the cultures
were exposed to an equal volume of the vehicle DMSO
(Sigma-Aldrich-Aldrich) during the course of the ex-
periment which was carried out at 37 °C, 5% CO2, and
at 95% relative humidity. After 24 h, cells were fixed
with 4% paraformaldehyde (PFA; for 10 min at RT),
washed 3 times with phosphate buffer saline (PBS,
pH 7.4) and the non-migratory cells on the upper
membrane surface were removed with a cotton swab.
The presence of transmigrated OPCs in the lower
chamber was evaluated by immunostaining with Olig2
antibody (1:200, AB9610 Millipore) and its corre-
sponding fluorescent secondary antibody. After immu-
nostaining, the Boyden filters were examined and
images were digitally captured using a Leica DM6000
microscope-coupled coolsnap camera and visualized
with Metamorph 5.0 software (Molecular Devices). To
quantify chemokinesis, 16 fields per well (×20 object-
ive) taken randomly were photographed and the num-
ber of transmigrated OPCs per field was counted using
ImageJ 1.49e software (NIH). The data were expressed
as number of migrating OPCs per mm2 ± standard
error to the mean (SEM).
Production of proteolytically inactive tPA (GGACK tPA)
GGACK (1,5-dansyl-L-glutamyl-L-glycyl-L-arginine chlor-
omethylketone; EMD) was added to Actilyse (Boehringer-
Ingelheim) in a fourfold molar excess. The solution was
allowed to react for 24 h at room temperature and dia-
lysed for 48 h at 4 °C with PBS to remove all unbound
GGACK. The actilyse buffer was reconstituted with argin-
ine monohydrochloride (Sigma-Aldrich-Aldrich) added to
GGACK-tPA. Finally, the lack of proteolytic activity of
GGACK-tPA was confirmed with a spectrozyme assay
(American Diagnostica).
Immunoblotting
After dissociation with ice-cold TNT buffer (50 mM
Tris–HCl pH 7.4; 150 mM NaCl; 0.5% Triton X-100),
cells were centrifuged (12,000 g, 4 °C, 15 min) and pro-
tein content assessed by the BCA method (Pierce,
France). Proteins (20 μg) were separated by 10% SDS-
PAGE and transferred onto a PVDF membrane. Mem-
branes were blocked with TBS (10 mM Tris; 200 mM
NaCl; pH 7.4) containing 0.05% Tween-20, 5% BSA,
and incubated overnight at 4 °C with primary anti-
bodies against Erk 1/2 (42 kDA) and phosphorylated
Erk 1/2 (42 kDA) (Cell signaling). After incubation with
the anti-rabbit peroxydase-conjugated secondary anti-
bodies (1:50000), proteins were visualized with an en-
hanced chemiluminescence ECL-Plus detection system
(Perkin ElmerNEN, France).
Statistical analysis
All results are expressed as mean ± SEM. For in vitro
experiments, the n value corresponds to n different well
pools derived from independent dissections. For group
comparison, Kruskal-Wallis tests were used followed by
Mann–Whitney U-tests as post hoc tests.
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Results
Migration of OPC is delayed in tPA−/− mice during spinal
cord and corpus callosum development
Our first step was to estimate the effects of the invali-
dation of tPA gene on ventral OPCs migration during
spinal cord development (Fig. 1). The ventral OPCs ori-
ginate from the motor neuron progenitor (pMN) do-
main that first produces motor neurons followed by
OPCs [20]. We observed a lower number of Olig2+
cells in the spinal cord parenchyma, outside the pMN
domain, in tPA−/− mice than in wild type mice at E13
(WT: 117.61 ± 5.34 vs tPA−/−: 44.90 ± 8.87, p = 0.0339),
E15 (WT: 342.67 ± 5.69 vs tPA−/−: 276.62 ± 16.41, p =
0.0339) and E17 (WT: 2517.52 ± 107.76 vs tPA−/−:
1990.55 ± 109.47, p = 0.0209) (Fig. 1a and corresponding
quantifications, Fig. 1b). There was no significant differ-
ence between wild type and tPA−/− mice at P0 (WT:
1957.72 ± 46.20 vs tPA−/−: 2216.869 ± 167.66, p = 0.1489)
(Fig. 1a and corresponding quantifications, Fig. 1b). Con-
versely, a higher number of Olig2+ OPCs remained in the
pMN domain, in tPA−/− mice than in wild type mice at
E13 (WT: 4854.75 ± 345.08 vs tPA−/−: 5889.12 ± 30.20, p =
0.0339) (Fig. 1c and corresponding quantification, Fig. 1d).
There was no significant difference between wild type and
tPA−/− mice at E15 (WT: 2632.84 ± 192.33 vs tPA−/−:
2230.11 ± 202.74, p = 0.4795). Olig2+ cells were not
detected inside the pMN domain at E17 and P0, (Fig. 1c
and corresponding quantifications, Fig. 1d). This effect
was not due to an action of tPA on OPC proliferation, as
the number of Ki67+/Olig2+ proliferating OPCs was not
Fig. 1 Migration of OPC is delayed in tPA−/− mice during spinal cord development. a Photomicrographs from spinal cord sections show
representative images (from 3–4 mice) of Olig2 immunostaining (red) and DAPI staining (blue) in the spinal cord (right ventral horn) of WT
(left column) and tPA−/− (right column) mice at E13, E15, E17 and P0. b Corresponding quantifications of Olig2+ oligodendrocytes (mean ± SEM,
n = 3–4 per group; *p < 0.05). c Photomicrographs from tissue sections show representative images (from 3–4 mice) of Olig2 immunostaining
(red) and DAPI staining (blue) in pMN domain of WT (left column) and tPA−/− (right column) mice at E13, E15, E17 and P0. d Corresponding
quantifications of Olig2+ oligodendrocytes (mean ± SEM, n = 3–4 per group; *p < 0.05). e Quantification of the percentage of proliferating OLs
(Ki67+/Olig2+) in the spinal cord parenchyma (right ventral horn and pMN domain) (mean ± SEM, n = 3–4 per group). E: embryonic day; ec:
ependymal canal; ND: not detected; OL: oligodendrocyte; P: postnatal day; pMN domain: motor neuron progenitor domain; RVH: right ventral horn;
WT: wild type. tPA−/−: tPA Knock-out. Scale bars: 20 μm
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altered in tPA−/− mice, either within or outside the pMN
at E13 (Fig. 1e). These data suggest that the lower num-
ber of OPCs outside the pMN observed in the spinal
cord of tPA−/− mice is due to a delay in the migration
ability of OPCs. We then asked whether this effect of
tPA is restricted to the spinal cord or could also be im-
portant for the development of other brain regions. To
answer this, we used the same strategy as before to as-
sess OPC migration in the telencephalon of mice be-
tween E15 and P0 (Fig. 2), at stages of corpus callosum
formation. In accordance with what observed in the
spinal cord, we observed a lower number of Olig2+ cells
in the telencephalon parenchyma in tPA−/− mice as com-
pared to wild type mice at E15 (WT: 179.21 ± 22.48 vs
tPA−/−: 120.54 ± 2.49, p = 0.0495) and E17 (WT: 342.73
± 42.56 vs tPA−/−: 232.22 ± 13.35, p = 0.0495) (Fig. 2a
and corresponding quantifications, Fig. 2b). At P0, this
wave of OPC migration stopped, as reflected by a decrease
in the number of Olig2+ both in wild type and tPA−/− ani-
mals. This trend occurred with a delay in tPA−/−, resulting
in a higher number of Olig2+ cells in tPA−/− at P0 (WT:
114.82 ± 9.48 vs tPA−/−: 151.13 ± 9.20 p = 0.0495). To-
gether, these data show that tPA deletion leads to a delay
in the migration of OPCs during the formation of the
spinal cord and the corpus callosum.
Our next step was to determine the cellular origin of
tPA during development in wild type mice (Fig. 3). tPA
expression in mature oligodendrocytes did not occur
before P0 (Fig. 3a), confirming previous reports in adult
mice [11]. However, tPA was expressed in Sox2+ neural
stem cells of the pMN (Fig. 3b) and in CD31+ endothe-
lial cells (Fig. 3c) within the whole spinal cord from the
early stages of spinal cord development (E13) to P0.
Then, because OPC migration has been shown to be
guided by endothelial cells during development [21], we
hypothesized that invalidation of tPA may result in loss
of OPC tropism for endothelial cells. We focused on
embryonic day 13 to study oligovascular interactions be-
cause E13 signs the beginning of the first wave of OPC
migration in the mouse spinal cord [22] and because the
biggest difference in oligodendrocyte migration between
wild type and tPA−/− were observed at this stage
(Fig. 1a-b). First, in the right ventral horn of spinal cord
in wild type mice, we observed that a substantial propor-
tion of Olig2+ cells (Fig. 4a) was found at the vicinity
(<10 μm) of vessels at E13. In tPA−/− mice, we found
significantly less OPCs at the vicinity of vessels than in
wild type mice (WT: 38.86 ± 2.02 vs tPA−/−: 31.33 ± 1.25,
p = 0.0495) (Fig. 4b, and corresponding quantification
Fig. 4c). Of note, the number of vessels was not altered
in tPA−/− mice as indicated by quantification of the sur-
face occupied by CD31 immunostaining (WT: 3.76 ± 015
vs tPA−/−: 3.79 ± 0.13, p = 0.8273) (Fig. 4d).
Migration of OPC is delayed in tPA−/− mice during
remyelination after white matter lesion in adult mice
Because remyelination after lesion of the white matter
shares mechanistic features with myelination during
development [9, 10], we then addressed the possible in-
volvement of tPA in remyelination. To do so, we in-
duced focal white matter lesions in adult mice by
stereotactic injection of lysolecithin directly in the cor-
pus callosum [23]. As seen with MRI analysis, this in-
duced the formation of a white matter lesion (Fig. 5a),
followed by progressive recovery along time from 3 to
Fig. 2 Migration of OPC is delayed in tPA−/− mice during corpus
callosum development. a Photomicrographs from tissue sections
show representative images (from 3 mice) of Olig2 immunostaining
(red) and DAPI staining (blue) in the telencephalon of WT (left column)
and tPA−/− (right column) mice during corpus callosum development
at E15, E17, P0 and P3. Dotted lines show corpus callosum limits.
b Corresponding quantifications of Olig2+ oligodendrocytes
(mean ± SEM, n = 3 per group; *p < 0.05). E: embryonic day; OL:
oligodendrocyte; P: postnatal day; WT: wild type. Scale bars: 100 μm
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21 days post injection (dpi) (Fig. 5a and corresponding
quantification, Fig. 5b). At 3 dpi, tPA−/− presented larger
lesions than wild type mice (WT: 0.71 ± 0.05 mm3 vs
tPA−/−: 1.18 ± 0.13 mm3, p = 0.009) (Fig. 5a and corre-
sponding quantification, Fig. 5b). However, at 1dpi, lesion
size was equivalent in wild type and tPA−/− animals (WT:
0.78 mm3 ± 0.09 vs tPA−/−: 0.91 ± 0.05 mm3, p = 0.1745)
(Fig. 5a and corresponding quantification, Fig. 5b) which
indicates that the larger lesions in tPA−/− at 3 dpi are due
to a prolonged progression of the lesion. In fact, at 3 dpi,
recovery had already started in wild type animals, while
the lesion continued growing in tPA−/− animals (Fig. 5a
and corresponding quantification, Fig. 5b). White matter
lesions were still larger in tPA−/− at 7 dpi (WT: 0.49 mm3
± 0.08 vs tPA−/−: 0.82 mm3 ± 0.09, p = 0.0283) (Fig. 5a
and corresponding quantification, Fig. 5b), to eventually
reach equivalent size a 14 dpi (WT: 0.5 ± 0.07 vs tPA−/−:
0.49 ± 0.12, p = 0.9168). This suggests a delayed recovery
in tPA−/− animals, which could be due to a defect in
OPC migration. Indeed, we observed that the number of
Olig2+ cells was lower in tPA−/− at 3dpi, 7dpi and 14 dpi,
and reached equivalent values at 21dpi (WT: 0.41 ± 0.11
vs tPA−/−: 0.34 ± 0.04, p = 0.7540) (Fig. 5c and corre-
sponding quantification, Fig. 5d). This effect was not due
to an action of tPA on OPC proliferation, as the number
of Ki67+/Olig2+ proliferating OPCs was not altered in
tPA−/− at 3dpi (Fig. 5e). No difference was observed in
the number of Olig2+ cells in the contralateral corpus
callosum at these times (Additional file 2: Figure S1).
We asked whether these differences in the number of
Olig2+ cells within the lesion could result in differences
in remyelination. At 14 dpi, wild type and tPA−/− corpus
callosum showed comparable MBP staining with a
remaining lesion in the ipsilateral corpus callosum (WT:
2110.94 ± 79.37 vs tPA−/−: 2143.10 ± 354.94, p = 0.8273)
(Fig. 5f and corresponding quantification, Fig. 5g), indi-
cating that remyelination was incomplete in wild type
and tPA−/− animals at this stage. At 21dpi, in wild type
animals, MBP staining increased in the ipsilateral to
reach an intensity close to the contralateral, unlesioned
hemisphere, and the lesion mostly disappeared (Fig. 5f
and corresponding quantification of MBP staining,
Fig. 3 tPA expression during spinal cord development. Photomicrographs from spinal cord sections show representative images (from 3 mice) of
tPA (red) with (a) Olig2 (green), (b) Sox2 (green), and (c) CD31 (right column, green) immunostaining in the spinal cord of wild type mice at E13,
E15, E17 and P0. Asterisks show colocalization of tPA and CD31 immunoreactivity in endothelial cells. Filled arrowhead shows colocalization of
tPA and Olig2 immunoreactivity oligodendrocytes. E: embryonic day; P: postnatal day. Scale bars: 20 μm
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Fig. 5g), which indicates effective remyelination between
14 and 21 dpi. In contrast, in tPA−/− animals, MBP stain-
ing did not increase between 14 and 21 dpi and a lesion
remained in the corpus callosum (Fig. 5f and corre-
sponding quantification of MBP staining, Fig. 5g), which
indicates that remyelination was mostly ineffective
between 14 and 21 dpi. Together, these data show that
the delay in OPC migration in tPA−/− is associated to a
defect in remyelination.
We next addressed the question of the cellular origin of
tPA during post-lesion remyelination (Fig. 6). tPA expres-
sion was found around the lesion in wild type mice in
endothelial CD31+ cells and in some Olig2+ oligodendro-
cytes at all tested stages (1–21 dpi), but not in Iba1+ or
GFAP+ cells (Fig. 6). Similar to what previously observed
during developmental myelination, oligodendrocyte migra-
tion took place preferentially along the vessels (Fig. 7a) at 3
dpi and this tropism of oligodendrocyte for vessels was
reduced in tPA−/− mice as compared to wild type mice
(WT: 25.57 ± 2.39 vs tPA−/−: 15.51 ± 3.79, p = 0.0495)
(Fig. 7b and corresponding quantification of MBP staining,
Fig. 7c). As previously observed during developmental
myelination, the area of CD31+ staining was equiva-
lent in the lesion in wild type and tPA−/− mice (WT:
1.52 ± 0.27 vs tPA−/−:1.21 ± 0.07, p = 0.5127) (Fig. 7d),
indicating that the number of vessels was not altered
in tPA−/− animals.
tPA exerts chemokinetic effects via its EGF-like domain
The above data show that the loss of tPA drives a delay in
developmental myelination and in remyelination after
white matter lesion. This suggests that endogenously pro-
duced tPA participates in promoting (re)myelination. To
confirm that tPA could drive this effect by promoting the
migration of OPCs, we used an in vitro system designed
to assess chemokinesis of cultured OPCs (Fig. 8). We
showed that tPA promoted the migration of OPCs in a
dose dependent manner (0.1- 10 μg/ml), while tPA vehicle
did not induce any effect (Fig. 8a and corresponding
quantification Fig. 8b). At the highest dose (10 μg/ml), the
effect of tPA on the migration of OPCs was equivalent to
what observed with the chemokinetic factor FGF2 (Fig. 8a
and corresponding quantification Fig. 8b). In accordance
to what observed in vivo (Fig. 5e), tPA did not exert this
effect by influencing OPC proliferation (Fig. 8c).
Finally, because EGFR activation in oligodendrocytes
can increase OPC migration [16] and because tPA was
reported earlier to activate EGFR on oligodendrocytes
[11], we hypothesized that the observed effects of tPA
on OPC migration implied EGFR activation.
Fig. 4 tPA promotes oligodendrocyte migration along vessels during development at times of intense migration. a Photomicrographs from spinal
sections show representative images (from 3 mice) of tPA (red), CD31 (green) and Olig2 (grey) immunostaining in the right ventral horn of WT
mice spinal cords at E13. Right image is a 3D reconstruction from confocal acquisitions (on the left). b Photomicrographs from tissue sections
show representative images (from 3 mice per group) of Olig2 (red), CD31 (green), and DAPI (blue) immunostaining in the right ventral horn of WT
and tPA−/− mice spinal cords at E13. c Quantification of the percentage of Olig2+ oligodendrocytes close (<10 μm) to vessels in the ventral spinal
cord parenchyma outside the pMN domain in WT and tPA−/− mice (mean ± SEM, n = 3 per group; *p < 0.05). d Quantification of the percentage
of CD31+ staining area in the ventral spinal cord parenchyma outside the pMN domain in WT and tPA−/− mice (mean ± SEM, n = 3 per group; *p < 0.05).
E: embryonic day; OL: oligodendrocyte; pMN domain: motor neuron progenitor domain; WT: wild type. Scale bars: 20 μm
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First, we investigated whether oligodendrocytes ex-
press EGFR, which would confer them potential respon-
siveness to EGF-like signals mediated by tPA. During
spinal cord development, EGFR was detected in the
pMN domain (ventral ventricular zone) (Fig. 9a) in
Olig2+/Sox2+ OPCs (Fig. 9b, Additional file 3: Figure S2)
at early stages of OPC migration (E13), a subset of these
cells being also positive for PDGFR-α (Additional file 3:
Figure S2). In all cases, OPCs lost EGFR staining at later
developmental stages, when they have left the pMN do-
main (Fig. 9a, Additional file 3: Figure S2). Interestingly,
EGFR+ OPCs were found at the vicinity of tPA
immunoreactivity within the pMN domain (Fig. 9a),
which was compatible with an interaction of tPA with
EGFR on OPCs. Concerning remyelination after white
matter lesion, EGFR was expressed in the damaged cor-
pus callosum from 3dpi, and this expression gradually
disappeared with time until 21dpi (Fig. 9c). Consistent
with a role of EGFR in the migration of OPCs, this
receptor was detected, in the remyelinating lesion, in
Olig2+/Sox2+ cells (Fig. 9d, Additional file 3: Figure S2).
Together, these data indicate that EGFR, in the condi-
tions studied here, is expressed in early, Olig2+/Sox2+
oligodendrocyte precursors.
Fig. 5 Remyelination is delayed in tPA−/− after white matter damage in adult mice. a Representative high resolution T2 images and b quantification
of the lesion size at 1, 3, 7, 14 and 21 days after lysolecithin injection (dpi) in the corpus callosum of WT and tPA−/− mice. (mean ± SEM, n = 5
per group; *p < 0.05 and **p < 0.01 significantly, Mann–Whitney U test). c Photomicrographs from corpus callosum sections (perilesion) show
representative images (from 3 mice) of Olig2 immunostaining (red) and DAPI staining (blue) from WT (left) and tPA−/− (right) mice at 3 days
post injection (dpi). (Scale bars: 20 μm). d Corresponding quantifications of Olig2+ oligodendrocytes (mean ± SEM, n = 3 per group; *p < 0.05).
e Quantification of the percentage of proliferating OLs (Ki67+Olig2+/Olig2+) in the lesion of WT and tPA−/− mice, 3 days post-injection. (mean
± SEM, n = 3 per group). f Photomicrographs from brain sections (corpus callosum lesion) show representative images (from 3 mice per group)
of MBP immunostaining (red) in the ipsilateral and contralateral corpus callosum of WT and tPA−/− mice, 14 and 21 days post-injection (dpi).
Dotted lines show quantified area limits. (Scale bars: 100 μm). g Corresponding quantifications of MBP fluorescence intensity (mean ± SEM,
n = 3 per group; *p < 0.05). AU: arbitrary unit; dpi: days post injection; OL: oligodendrocyte; WT: wild type. tPA−/−: tPA Knock-out
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Our last step was to address the implication of EGFR
in tPA effects in our chemokinesis assay in vitro. We
confirmed that cultured OPCs express EGFR (Fig. 9e).
As described before (Fig. 8), tPA (10 μg/ml) induced a
chemokinetic effect equivalent to the typical chemokine
FGF2 (Fig. 9f ). Noteworthy, while the EGFR inhibitor
AG1478, when added alone, did not induce any effect
on OPC migration, it reversed the chemokinetic effect
of tPA (Fig. 9f ). In contrast, OPC migration was not
modified when the enzymatic activity of tPA was
blocked by the inhibitory peptide GGACK (Fig. 9f ).
Finally, tPA treatment in OPC induced an early (from
5 min) and transient phosphorylation of the extracellular-
regulated kinases (Erk), a downstream effectors of the
EGFR pathway (Fig. 9g), as reported earlier [11]. Together,
these data show that tPA can promote chemokinetic ef-
fects on OPCs via the protease-independent activation of
EGFR.
Discussion
The present study reports the effects of tPA on the migra-
tion of OPCs during embryonic development and during
remyelination after white matter lesion. We show that, in
both situations, OPC migration is delayed in tPA−/−
animals. This was illustrated by a lower number of
OPCs leaving the pMN zone (spinal cord development) or
reaching the remyelinating corpus callosum (post-lesion
recovery) in tPA−/− mice. During development and re-
generation, we observed that tPA was expressed in
vessels. Interestingly, in both cases, OPC migration
occurred along vessels and the proportion of OPCs
surrounding these vessels was reduced in tPA−/− animals.
Finally, we highlighted the role of EGFR signaling in
these processes by showing that EGFR was expressed
on migrating OPCs and that, in vitro, tPA exerted a
chemokinetic effect on OPCs which was mediated by
the activation EGFR.
The involvement of tPA in the migration of neurons
during development of the CNS has been first shown
more than 15 years ago [14] and has been confirmed
later [24]. The present study brings new advances by
showing that oligodendrocyte migration is also facili-
tated by tPA. In fact, tPA increases the migration of
several other cell types, within or outside the central and
peripheral nervous system, such as macrophages [25, 26]
or cancer cells [27]. However, in the CNS, while most
studies report the influence of tPA on migration during
development, the issue of how the pro-migratory effects
of tPA can influence pathological situations has been
scarcely addressed [28]. Our study brings new elements by
Fig. 6 tPA expression after white matter damage in wild type mice. Photomicrographs from tissue sections show representative images of tPA (red), GFAP
(green, first column), Iba1 (green, second column), CD31 (green, third column), Olig2 (green, fourth column) and DAPI staining (blue) immunoreactivities
in the remyelinating corpus callosum of WT mice, 1, 3, 7, 14 and 21 days after lysolecithin injection. Asterisks show colocalization of tPA and CD31
immunoreactivities in endothelial cells. Filled arrowheads show colocalization of tPA and Olig2 immunoreactivities in oligogendrocytes.
(Representative images, n = 3 per group). dpi: days post injection. Scale bars: 20 μm
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highlighting the potential role of tPA on oligodendrocyte
migration during white matter damage. This suggests
implication for several pathologies in which white matter
is damaged, such as multiple sclerosis, leukodystrophies,
periventricular leukomalacia, white matter stroke, head
trauma or spinal cord injury.
Interestingly, in our study, we show that tPA invalidation
leads to a delay in oligodendrocyte migration during
development and after white matter demyelination. This
suggests that, despite the fact that the oligodendrocyte pop-
ulations involved in these two situations are different [29],
their chemokinetic response to tPA would be equivalent.
Pro-migratory effect of tPA was observed in the corpus
callosum and in the spinal cord, which suggests equivalent
responses in these two regions of the CNS. Thus, tPA
appears to rise homogeneous responses in oligodendrocytes
migration regardless of the age (embryo, adult), region
(telencephalon, spinal cord) or pathological state.
Fig. 8 tPA induces chemokinesis on cultured OLs. a Rat primary cultures of OPCs were seeded on the upper compartment of Boyden chambers
and treated in indicated conditions for 24 h. Photomicrographs show representative fields of the lower compartment after Olig2 immunostaining
(green; representative image, n = 9, three independent cultures). b Oligodendrocyte chemokinesis was estimated by counting cells in the lower
compartment in control conditions or in the presence of 0.2 μg/mL FGF2, 0.1-10 μg/mL tPA or tPA vehicle. (mean ± SEM; n = 9, three independent
cultures; *p < 0.05 and **p < 0.01). c OL proliferation (percentage) during 24 h was estimated by measuring mitochondrial activity with WST-1
test after treatment or not. Control is the basal OL proliferation during 24 h without treatment (mean + SEM; n = 15, five independent cultures).
OPC: oligodendrocyte precursor cell; ns: not significant. Scale bars: 100 μm
Fig. 7 tPA promotes oligodendrocyte migration along vessels after white matter damage. a Photomicrographs from brain sections show
representative images (from 3 mice) of tPA (red), CD31 (green) and Olig2 (grey) immunostaining in the corpus callosum lesion of WT mice at
3 days post injection (3 dpi). Right image is a rotation of 3D reconstruction from confocal acquisitions (on the left). b Photomicrographs from
tissue sections show representative images (from 3 mice per group) of Olig2 (red), CD31 (green), and DAPI (blue) immunostaining in the corpus
callosum (perilesion) of WT and tPA−/− mice spinal cords at 3 days post injection (3 dpi). c Quantification of the percentage of Olig2+ oligodendrocytes
close (<10 μm) to vessels in the in the corpus callosum (perilesion) in WT and tPA−/− mice (mean ± SEM, n = 3 per group; *p < 0.05). d Quantification
of the percentage of CD31+ staining area in corpus callosum (perilesion) in WT and tPA−/− mice (mean ± SEM, n = 3 per group; *p < 0.05). E: embryonic
day; OL: oligodendrocyte; pMN domain: motor neuron progenitor domain; WT: wild type. Scale bars: 10 μm
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Although the mechanism of action of tPA on migra-
tion was suggested before to involve proteolytic degrad-
ation of the extracellular matrix [24], our data show that
tPA can also exert protease independent chemokinetic
effects on OPCs by activating the EGFR. Several previ-
ous in vitro studies reported protease-independent
Fig. 9 tPA induces chemokinesis on OLs via its EGF-like domain. a Photomicrographs from WT mice tissue sections show representative images of
tPA (red), EGFR (green) and Olig2 (blue) immunoreactivities in the ventral ventricular zone of mice spinal cords at E13, E15, E17, P0, P3 and P7.
Dotted lines show ependymal canal limits. (Representative images, n = 3 per group). b Photomicrographs from WT mice tissue sections show
representative images of EGFR (green) and Olig2 (blue) immunoreactivities in the pMN domain of mice spinal cords at E13. The inlet shows 3D
reconstruction from confocal acquisition. (Representative images, n = 3 per group). c Photomicrographs from WT mice tissue sections show
representative images of tPA (red), EGFR (green) and Olig2 (blue) immunoreactivities in the contralateral (left column) and ipsilateral (right column)
corpus callosum of adult mice, 3, 7, 14 and 21 days after lysolecithin injection. Full lines show lateral ventricle limits and dotted lines show corpus
callosum limits. (Representative images, n = 3 per group). d Photomicrographs from adult WT mice tissue sections show representative images of
EGFR (green) and Olig2 (blue) immunoreactivities in the lesion 3 days after injection. (Representative images, n = 3 per group). e Rat OPCs were
cultured for 24 h. Photomicrographs show representative fields after Olig2 (red) and EGFR (green) immunostaining or the merged images (yellow).
(representative images, n = 3 per group). f Rat primary cultures of OPCs were seeded on the upper compartment of Boyden chambers and
treated in indicated conditions for 24 h. g Proteins from cultured OPCs treated with tPA (10μg/ml) or corresponding vehicle for indicated times
were subjected to western blot for the phosphorylated (P-Erk) or total (Total Erk) forms of Erk. Chemokinesis was estimated by counting cells in
the lower compartment in control conditions or in the presence of 0.2 μg/mL FGF2, 10 μg/mL tPA, 10 μg/mL tPA + 5 μM inhibitor of the kinase
activity of EGFR (AG1478), 5 μM AG1478, 10 μg/mL tPA complexed with the proteolytic inhibitory peptide GGACK. (mean ± SEM; n = 9, three
independent cultures; *p < 0.05, Mann–Whitney U test). cc: corpus callosum; dpi: days post injection; E: embryonic day; LV: lateral ventricle; OPC:
oligodendrocyte precursor cell; P: postnatal day. Scale bars: 20 μm
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effects of tPA on neurons [30–32] and oligodendrocytes
precursors [11] via a mechanism termed as cytokine- or
growth factor–like. In OPCs, EGF receptor activation by
tPA was shown to mediate antiapoptotic effects, thus
sustaining protection of the white matter after experi-
mental ischemic stroke [11]. The present study indicates
that tPA can also exert pro-migratory effect on OPCs by
activating EGFR. Several differences in the experimental
approach explain why pro-migratory, rather than anti-
apoptotic effects are unveiled in the present work. First,
the lesion model used here is based on the detergent
properties of lysolecithin which toxic effects largely sup-
plants apoptosis. In effect, the lesion size at 1dpi is
mostly similar in wild type and tPA−/− animals, and the
effect of tPA invalidation appears only from 3dpi, when
OPC migration and remyelination starts. Second, our
study addresses the effect of endogenous tPA, while in
previous works [11] tPA was injected to the animals.
The impact of tPA injection largely differs from that of
endogenous tPA in terms of dose, timing and accessibil-
ity to injured tissues. Finally, the timing in which the
study was conducted is also different: while in the Correa
et al. paper, the impact of tPA injection was assessed in
the subacute phase (1 day post ischemia), in the present
study, histological analysis were performed in subacute
and chronic phases (up to 21dpi), which enables observing
tissue regeneration, in particular OPC migration.
The activation of EGFR pathway has been previously
described as an activator of OPC migration. Migratory
NG2+ cells express more EGFR than non-migratory cells
[16] and overexpression in non-migratory cells prompts
them to migrate [16]. Accordingly, EGFR-expressing
retinal progenitor cells show increased chemokinesis in
the presence of EGF [33]. In the context of white matter
lesion, overexpression or invalidation of EGFR signaling in
oligodendrocytes respectively accelerate [34] or reduces
[35] remyelination after focal demyelination of corpus cal-
losum. In light of these findings, the effect of intranasal
EGF treatment was tested in a mouse model of preterm
diffuse white matter injury [36]. This treatment led to en-
hanced generation of OPCs, leading to functional recovery
[36]. Chemokinetic effects were proposed to sustain these
effects of EGFR signaling activation, as EGF induces
neural precursor cells to differentiate to glial cells and to
acquire a motile phenotype [37]. In our study, we suggest
that this EGFR-dependent pathway could be activated by
tPA to exert pro-migratory effects on OPCs in patho-
logical conditions where white matter is damaged, without
inducing hyperplasia of OPCs as reported when EGFR is
constitutively expressed [38].
The increase in the number of OPCs during remyelina-
tion upon EGFR activation has been suggested in the past
to occur via increased proliferation, enhanced differenti-
ation from neural progenitors, migration or combinations
of these different mechanisms [39–41]. Here we show
that tPA does not influence OPC proliferation in vitro,
but rather enhances their migration via a chemokinetic
dependent on the activation of EGFR. One possibility to
explain this difference is that the activation of EGFR by
tPA, by its natural ligand (EGF) or by genetic strategies
can induce different response in target cells, in particular
because the degree of activation of downstream targets in
these different situations may vary considerably.
Our in vitro data suggest that tPA mediates its promi-
gratory effects, at least in part, by activation of EGFR
and independently of its proteolytic activity. Nevertheless,
proteolytic effects have also been suggested: tPA was
shown to proteolytically activate proBDNF into mature
BDNF, which increases proliferation of OPCs in vitro [42]
andpromotes remyelination when injected intra veinously
after WM stroke [43]. In our hands, tPA invalidation did
not modify proliferation of OPC, which claims for a differ-
ent mechanism. Activation of growth factor pathways by
tPA can also occur by a regulation of expression, rather
than maturation: tPA upregulates vascular endothelial
growth factor (VEGF) by endothelial cells [44] which
others have reported to promote the migration of oligo-
dendrocyte precursor cells in vitro [45, 46]. Notheworthy,
whether the VEGF pathway targets OPC proliferation [47]
or not [46] is still a matter of debate. In any case, we re-
port here that tPA deficiency did not influence OPC pro-
liferation. Further studies may help decipher possible links
between tPA and the VEGF pathway in OPC migration in
vivo, during development and/or remyelination.
The previous point highlights the possible cooperative
role between endothelial cells and OPCs during (re)mye-
lination. This has led to the concept of « oligovascular
niche » [48]: vascular cells would secrete soluble factors
(including VEGF) which promotes migration and sur-
vival of oligodendrocytes [49]. Because tPA is mainly
produced by endothelial cells, it could be one of these
oligotrophic factors. In our hands, the common cellular
source of tPA in development and adult remyelination
was endothelial cells, which corroborates a possible role
of endothelial-derived tPA in the observed effects on
OPC migration. This is particularly relevant to the in-
creasing literature describing that migration of progenitor
cells, including OPCs, is guided by vessels. Blood vessels
form a scaffold for migration of neuroblasts to the adult
olfactory bulb [50], and more recently, a similar mechan-
ism has been described specifically for OPCs migration
[21]. A cooperation between vessels and progenitors
exists, in which neural progenitors (including OPCs)
induce local angiogenesis while migrating, which in turns
facilitates progenitor emigration from the niche [51]. This
« vasophilic » migration [50] was described during devel-
opment in previous studies, but the present work is to our
knowledge the first to describe it during remyelination
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after white matter lesion. This is particularly interesting
in regard to the description of perivascular tPA deposits
in acute MS lesions [52], a type of demyelinated plaque
where remyelination may succeed spontaneously.
Pericytes have also been suggested to influence OPC
migration [53], which raises the question of the expression
of tPA in pericytes. During development, we did not detect
pericytes in the developing spinal cord at E13, when the
phenotypic differences between wt and tPA−/− first occurred
(data not shown), which is likely due to the immaturity of
the vessels of the spinal cord at this stage, in which pericytes
are usually not reported [54–56]. After white matter lesion,
tPA was not detected in pericytes surrounding blood vessels
at 3 dpi (Additional file 4: Figure S3), when the delay in
OPC migration was observed in tPA−/− as compared to wt
mice. This is in accordance with our previous report of the
absence of tPA in adult pericytes [12]. Nevertheless, we not
cannot exclude with certitude that tPA is not expressed in
pericytes, and this should be the purpose of future studies.
This link between angiogenesis and OPC migration is
relevant to white matter pathology, in particular multiple
sclerosis, in which angiogenesis has been described [57].
tPA could be involved in these processes in regard to a
previous study in experimental autoimmune encephalomy-
elitis, a model of multiple sclerosis, in which recovery is re-
duced in tPA−/− animals [58]. Noteworthy, while wild type
animals showed remyelination in late phases of the disease,
this remyelination was severely reduced in tPA−/− animals
[58]. The present study brings new elements in a model
where demyelination is the primary insult:we here show
that the delay in OPC migration to the damaged area re-
sults in reduced remyelination in tPA−/− mice. This
strengthens the idea that the failure in recovery in tPA−/− in
EAE could be the result of a reduced capacity of remyelina-
tion. Overall, the present data suggest that endogenous tPA
could be important for remyelination in multiple sclerosis.
In accordance with this, tPA activity has been shown to be
decreased in post-mortem tissues from MS patients [59],
alleging that a drop of tPA may participate in reducing the
opportunity of remyelination in MS patients.
Conclusion
The present study shows that tPA provides chemokinetic
effects on OPCs. This effect leads to facilitating migration
of these cells during CNS and remyelination after white
matter lesion. Our in vitro results suggest that this effect is
mediated by the activation of EGFR, expressed on OPCs,
by the virtue of the EGF-like domain contained in tPA
structure. These results highlight the potential role of tPA
on OPCs in situation of white matter lesion. They suggest
that, in combination with previously described anti-
apoptotic activity, the chemokinetic effects of tPA could
be targeted to improve myelin recovery in pathological
conditions.
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Additional file 1: Table S1. Antibodies used in the study. Each
antibody used in this study is listed together with its supplier, species,
type (monoclonal/polyclonal), dilution and reference. (DOCX 16 kb)
Additional file 2: Figure S1. Oligodendrocyte number in the contralateral
corpus callosum of tPA−/− and WT mice. Quantification of OLs (Olig2+) in the
contralateral corpus callosum of WT and tPA−/− mice, 3, 7, 14 and 21 days
after lysolecithin injection (mean + SEM, n = 3 per group). dpi: days post
injection; OL: oligodendrocyte; WT: wild type. (TIF 523 kb)
Additional file 3: Figure S2. EGFR is expressed in early oligodendrocyte
precursors. Photomicrographs from embryonic spinal cord (ventral
ventricular zone, E13) and perilesional adult corpus callosum (3dpi)
WT mice tissue sections show representative confocal images of EGFR
(green), Sox2 or PDGFRα (red) and DAPI (blue) immunoreactivities.
Asterisks indicate PDGFRα+/EGFR− cells and arrowheads indicate
PDGFRα+/EGFR+ cells (Representative images from n = 3). Scale bars:
10 μm. (TIF 585 kb)
Additional file 4: Figure S3. tPA is not detected in PDFGR-β+ pericytes.
(A) Photomicrographs from adult WT mice tissue sections show
representative confocal images of PDGFR-β (green), tPA (red) and
DAPI (blue) immunoreactivities in the lesion 3 days after injection.
(Representative images from n = 3). Inlets show side view reconstructions
of the z-stack. (B) Representative fluorescent intensity/distance graph
measured from confocal image in (A) showing that tPA (Red) is not
found in colocalization with PDGFR-β staining. (TIF 328 kb)
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